GC
PJP icon

Grimes & Company’s Invesco Pharmaceuticals ETF PJP Stock Holding History

Grimes & Company’s Portfolio PJP Stock Details PJP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,804
Closed -$502K – 466
2025
Q4 		$502K Buy
+4,804
New +$483K 0.01% 310
2025
Q2 		– Sell
-3,492
Closed -$302K – 423
2025
Q1 		$302K Sell
3,492
-796
-19% -$67.8K 0.01% 293
2024
Q4 		$354K Buy
+4,288
New +$369K 0.01% 291

Other funds holding PJP

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
PAM
Peak Asset Management Louisville, Colorado $567M AUM 16.44% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
CI
Cavalier Investments Alpharetta, Georgia $3.7B AUM 51.42% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Grimes & Company's PJP Position: Q1 2026 in Review

Grimes & Company sold out of Invesco Pharmaceuticals ETF (PJP) in Q1 2026, closing a stake of 4,804 shares — an estimated $502K sold.

Grimes & Company first reported a position in PJP in Q4 2024 and held it in 3 quarters. The position peaked at $502K in Q4 2025. 119 funds tracked by Wall St. Rank hold PJP as of Q1 2026.

  • Grimes & Company reported no remaining Invesco Pharmaceuticals ETF position as of Q1 2026 after selling out during the quarter.
  • Grimes & Company sold 4,804 Invesco Pharmaceuticals ETF shares in Q1 2026, an estimated $502K.
  • Grimes & Company first reported a position in Invesco Pharmaceuticals ETF in Q4 2024 and held it in 3 quarters.
  • Grimes & Company's Invesco Pharmaceuticals ETF position peaked at $502K in Q4 2025.
  • 119 funds tracked by Wall St. Rank held Invesco Pharmaceuticals ETF as of Q1 2026.

Based on Grimes & Company's 13F filing for Q1 2026, filed 21 Apr 2026.